Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1998 1
2009 7
2011 5
2014 2
2018 4
2019 4
2020 4
2021 4
2022 4
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription.
Dreano E, Burgel PR, Hatton A, Bouazza N, Chevalier B, Macey J, Leroy S, Durieu I, Weiss L, Grenet D, Stremler N, Ohlmann C, Reix P, Porzio M, Roux Claude P, Rémus N, Douvry B, Montcouquiol S, Cosson L, Mankikian J, Languepin J, Houdouin V, Le Clainche L, Guillaumot A, Pouradier D, Tissot A, Priou P, Mély L, Chedevergne F, Lebourgeois M, Lebihan J, Martin C, Zavala F, Da Silva J, Lemonnier L, Kelly-Aubert M, Golec A, Foucaud P, Marguet C, Edelman A, Hinzpeter A, de Carli P, Girodon E, Sermet-Gaudelus I, Pranke I; French CF Reference Network study group. Dreano E, et al. Among authors: guillaumot a. Eur Respir J. 2023 Oct 19;62(4):2300110. doi: 10.1183/13993003.00110-2023. Print 2023 Oct. Eur Respir J. 2023. PMID: 37696564
Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare CFTR variants: a viewpoint.
Burgel PR, Sermet-Gaudelus I, Girodon E, Kanaan R, Le Bihan J, Remus N, Ravoninjatovo B, Grenet D, Porzio M, Houdouin V, Le Clainche-Viala L, Durieu I, Nove-Josserand R, Languepin J, Coltey B, Guillaumot A, Audousset C, Chiron R, Weiss L, Fajac I, Da Silva J, Martin C; French CF Reference Network study group. Burgel PR, et al. Among authors: guillaumot a. Eur Respir J. 2024 Jan 25;63(1):2301959. doi: 10.1183/13993003.01959-2023. Print 2024 Jan. Eur Respir J. 2024. PMID: 38242629 No abstract available.
Respiratory recovery trajectories after severe-to-critical COVID-19: a 1-year prospective multicentre study.
Schlemmer F, Valentin S, Boyer L, Guillaumot A, Chabot F, Dupin C, Le Guen P, Lorillon G, Bergeron A, Basille D, Delomez J, Andrejak C, Bonnefoy V, Goussault H, Assié JB, Choinier P, Ruppert AM, Cadranel J, Mennitti MC, Roumila M, Colin C, Günther S, Sanchez O, Gille T, Sésé L, Uzunhan Y, Faure M, Patout M, Morelot-Panzini C, Laveneziana P, Zysman M, Blanchard E, Raherison-Semjen C, Giraud V, Giroux-Leprieur E, Habib S, Roche N, Dinh-Xuan AT, Sifaoui I, Brillet PY, Jung C, Boutin E, Layese R, Canoui-Poitrine F, Maitre B; RE2COVERI Study Group. Schlemmer F, et al. Among authors: guillaumot a. Eur Respir J. 2023 Apr 1;61(4):2201532. doi: 10.1183/13993003.01532-2022. Print 2023 Apr. Eur Respir J. 2023. PMID: 36669777 Free PMC article.
Association between Leflunomide and Pulmonary Hypertension.
Lacoste-Palasset T, Chaumais MC, Weatherald J, Savale L, Jaïs X, Price LC, Khouri C, Bulifon S, Seferian A, Jevnikar M, Boucly A, Manaud G, Pancic S, Chabanne C, Ahmad K, Volpato M, Favrolt N, Guillaumot A, Horeau-Langlard D, Prévot G, Fesler P, Bertoletti L, Reynaud-Gaubert M, Lamblin N, Launay D, Simonneau G, Sitbon O, Perros F, Humbert M, Montani D. Lacoste-Palasset T, et al. Among authors: guillaumot a. Ann Am Thorac Soc. 2021 Aug;18(8):1306-1315. doi: 10.1513/AnnalsATS.202008-913OC. Ann Am Thorac Soc. 2021. PMID: 33502958 Free article.
[Impact of COPD: from disability to exacerbations].
Chabot F, Zysman M, Perrin J, Mercy M, Guillaumot A, Gomez E, Kheir A, Chaouat A. Chabot F, et al. Among authors: guillaumot a. Presse Med. 2014 Dec;43(12 Pt 1):1353-8. doi: 10.1016/j.lpm.2014.08.009. Epub 2014 Oct 29. Presse Med. 2014. PMID: 25448123 Review. French.
Soluble TREM-1 plasma concentration predicts poor outcome in COVID-19 patients.
Gibot S, Lafon T, Jacquin L, Lefevre B, Kimmoun A, Guillaumot A, Losser MR, Douplat M, Argaud L, De Ciancio G, Jolly L, Touly N, Derive M, Malaplate C, Luc A, Baumann C, François B. Gibot S, et al. Among authors: guillaumot a. Intensive Care Med Exp. 2023 Aug 14;11(1):51. doi: 10.1186/s40635-023-00532-4. Intensive Care Med Exp. 2023. PMID: 37574520 Free PMC article.
Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs.
Valentin S, Maurac A, Sitbon O, Beurnier A, Gomez E, Guillaumot A, Textoris L, Fay R, Savale L, Jaïs X, Montani D, Picard F, Mornex JF, Prevot G, Chabot F, Humbert M, Chaouat A. Valentin S, et al. Among authors: guillaumot a. Eur Respir J. 2021 Nov 4;58(5):2004066. doi: 10.1183/13993003.04066-2020. Print 2021 Oct. Eur Respir J. 2021. PMID: 33875491 Free article.
COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study.
Montani D, Certain MC, Weatherald J, Jaïs X, Bulifon S, Noel-Savina E, Nieves A, Renard S, Traclet J, Bouvaist H, Riou M, de Groote P, Moceri P, Bertoletti L, Favrolt N, Guillaumot A, Jutant EM, Beurnier A, Boucly A, Ebstein N, Jevnikar M, Pichon J, Keddache S, Preda M, Roche A, Solinas S, Seferian A, Reynaud-Gaubert M, Cottin V, Savale L, Humbert M, Sitbon O; French PH Network PULMOTENSION Investigators. Montani D, et al. Among authors: guillaumot a. Am J Respir Crit Care Med. 2022 Sep 1;206(5):573-583. doi: 10.1164/rccm.202112-2761OC. Am J Respir Crit Care Med. 2022. PMID: 35549842 Free PMC article.
41 results